Extramedullary plasmacytoma of the tibial nerve: illustrative case Authors: Parsa Nilchian, Max Reed, Andrew B Yang, Gary Kocharian, Kai-Ming Fu Published: 2025 ABSTRACT AbstractBACKGROUNDExtramedullary plasmacytomas (EMPs) are rare plasma cell tumors forming outside the bone marrow. EMPs spread to soft tissues with a predilection for the head and neck region. Therefore, EMPs are rarely included in the differential for peripheral nerve sheath tumors (PNSTs). The authors discuss a case of tibial nerve sheath invasion by an EMP in the context of multiple myeloma (MM).OBSERVATIONSA 70-year-old female with MM presented with right leg pain and a suspected PNST of the tibial nerve. Imaging revealed a T1-hypointense lesion in the popliteal fossa. Resection was attempted, but frozen pathology revealed a plasma cell neoplasm with a high Ki-67 proliferation rate. The resection was halted due to the tumor’s infiltrative and hemorrhagic nature and its extensive encasement of the tibial nerve. Postoperatively, the patient received 5 fractions of radiation therapy and three courses of teclistamab, which she continued as an outpatient without complications.LESSONSThis case highlights a rare occurrence of peripheral nerve invasion by an EMP with the first documented involvement of the tibial nerve. This report suggests that EMPs should be considered in the differential diagnosis of PNSTs, particularly in MM patients. The present case underscores the need for intraoperative biopsies in PNST resection, as imaging features alone may not be fully diagnostic. https://thejns.org/doi/10.3171/CASE25104 Keywords: extramedullary plasmacytoma, tibial nerve, peripheral nerve tumor, multiple myelomaABBREVIATIONS: EBV = Epstein-Barr virus, EMG = electromyography, EMP = extramedullary plasmacytoma, FDG = fluorodeoxyglucose, MM = multiple myeloma, MPNST = malignant PNST, PCL = plasma cell leukemia, PNST = peripheral nerve sheath tumor, SUVmax = maximum standardized uptake value Plasmacytomas are rare plasma cell tumors, often seen as a complication of multiple myeloma (MM). Plasmacytomas are seen in 6%–20% of patients with MM.1–3 Given the myelomatous nature of plasmacytomas, they most commonly form in bones, where they are referred to as paraskeletal plasmacytomas. In rare cases, malignant plasma cells can spread hematogenously to soft tissue, where they form extramedullary plasmacytomas (EMPs). The presence of EMPs in patients with MM is associated with a more aggressive disease course, shorter progression-free survival, and shorter overall survival.1,4,5 Although EMPs involving peripheral nerves are exceedingly rare, several cases have been reported affecting nerves such as the sciatic,6 median,7 sural,7 and cranial nerves8 and cauda equina.9 Hu et al. further described a patient presenting with L5–S1 radiculopathy caused by an epidural EMP compressing the spinal nerve roots, in the absence of vertebral involvement.10 These cases underscore the importance of considering EMPs in the differential diagnosis of peripheral nerve lesions in patients with MM. EMP treatment guidelines depend on a variety of factors. Resection is recommended except in cases in which resection is not anatomically favorable or safe, in which case radiation therapy can be used.11 The current standard of care for EMP treatment in MM also includes conventional lymphoma/myeloma combination chemotherapy with alkylating agents. Data concerning the efficacy of novel immunomodulatory agents and monoclonal antibodies remain limited.4,12,13 In contrast to EMPs, peripheral nerve sheath tumors (PNSTs) originate directly from nerve sheath cells. They typically present with radiating neuropathic pain, weakness, and a palpable, tender mass. The subclassification of PNSTs includes benign tumors such as schwannomas and neurofibromas, malignant PNSTs (MPNSTs), and metastases.14 Diagnosing PNSTs can be challenging with imaging alone, given that all these lesions produce similar radiological findings.15 Therefore, obtaining an intraoperative biopsy is often an essential step in the management of PNSTs. Although 20% of all EMPs arise outside of the head and neck, there are only a few reported cases of primary EMPs in peripheral nerves.16 As such, EMPs are often excluded from the differential diagnosis of PNSTs. Here, we report a unique case of tibial nerve sheath invasion by an EMP in the setting of MM. Illustrative Case History and Presentation A 70-year-old woman with a past medical history of plasma cell leukemia (PCL) and MM resulting in multiple osteoporotic vertebral compression fractures presented to us with right leg pain and a suspected PNST of the tibial nerve. She was first diagnosed with PCL and MM 5 years prior to the current presentation and at the time initially received PAD (pomalidomide, dexamethasone, daratumumab) and VAD (vincristine, doxorubicin, dexamethasone) regimens with limited response. This was followed by autologous stem cell transplantation with melphalan and lenalidomide maintenance therapy. Despite an initial remission, she experienced multiple relapses, including marrow recurrence, requiring additional systemic therapies, including carfilzomib, pomalidomide, and daratumumab. Four years prior to the current presentation, she underwent a T3–8 kyphoplasty and a T11, L1–4 kyphoplasty due to osteolytic lesions associated with her MM. A PET scan 19 months prior to presenting to our team first revealed a fluorodeoxyglucose (FDG)–avid right knee lesion. Two and one-half months prior to the current presentation, she experienced worsening right-sided calf pain. The pain radiated to the right foot and toes. She rated the pain as waxing and waning with an intensity ranging from 5 to 10 out of 10. The patient described her pain as shooting and “electric” in character. Her pain was worse when standing and sitting and better with movement and changing positions. Treatment with gabapentin did not provide relief. She denied any weakness of her right lower extremity but reported numbness of the right foot. On examination, she had a palpable mass in the right popliteal fossa. No reflex abnormalities were detected, and the patient’s numbness was generalized along the distribution of the tibial nerve. Plantar flexion strength and Tinel’s sign at the popliteal fossa were not tested. The patient’s family and genetic history was unremarkable. Imaging Nineteen months prior to being referred to our team, a whole-body PET-CT scan had revealed a 1.4-cm FDG-avid mass in the posterior right knee with a maximum standardized uptake value (SUVmax) of 11.7 (Fig. 1A and B), which was suspicious for extramedullary disease. Whole-body MRI 4 months prior also illustrated a T1-hypointense, T2-hyperintense lesion in the posterolateral aspect of the right popliteal fossa, slightly increased in size to 1.6 cm. The mass was suspected to be a PNST. On presentation, our team obtained contrast MRI of the right knee, which demonstrated a 7.3 × 2.9 × 2.9–cm (craniocaudal × anteroposterior × transverse dimensions) mass within the posterior aspect of the knee extending from the level of the distal femoral diaphysis to the level of the femorotibial compartments (Fig. 2A–D). The lesion had heterogeneous T2 signal changes and corresponding isointense/slightly hypointense T1 signal intensity. Postcontrast images demonstrated marked enhancement, except for an area of nonenhancement located centrally and anteriorly in the inferior aspect. The mass arose from the tibial nerve and demonstrated fusiform thickening of the nerve with perineural edema. These findings were consistent with a PNST of the right tibial nerve. The high SUVmax of 11.7 on PET and the lesion’s rapid growth in size raised concern for an MPNST. Although an image-guided biopsy was considered, preoperative MRI showed that the tumor could not be reliably separated from the surrounding neural elements, raising significant concern for iatrogenic nerve injury. Given the risks, an open surgical approach was favored to enable direct visualization and intraoperative neuromonitoring. Initial PET images obtained 19 months prior to presentation. A: Axial PET scan showing the FDG-avid mass surrounding the tibial nerve. The arrow points to the mass surrounding the right tibial nerve. The mass measured up to 1.4 cm in the greatest dimension. B: Sagittal and coronal views of the same mass. Arrows highlight the lesion. Preoperative axial MR images. A:Isointense/slightly hypointense T1 signal intensity of the right femoral mass measuring approximately 7.3 × 2.9 × 2.9 cm (craniocaudal × anteroposterior × transverse dimension). B: Heterogeneous T2 signal intensity of the mass within the posterior aspect of the knee extending from the level of the distal femoral diaphysis to the level of the femorotibial compartments. C and D: Enlarged views of the T2 image. The arrow points to the mass in all panels. Surgery After discussion of risks, benefits, and complications of surgery, the patient agreed to undergo a resection of the suspected right tibial nerve sheath tumor. The patient received preoperative antibiotics and was placed prone under general anesthesia. Neuromonitoring with electromyography (EMG) and direct nerve stimulation was performed throughout the procedure. After the opening, care was taken to dissect the tumor from the surrounding structures, and the proximal and distal course of the tibial nerve was identified and isolated. Using a combination of EMG monitoring and direct stimulation, we carefully dissected the tumor free from its overlying fascial adhesions. The multiple fascicles of the nerve were identified, and these were stimulated identifying the peroneal and tibial branches. The tumor appeared to be invested in the right tibial nerve and elicited contractions of the gastrocnemius muscle. It was very firm and vascular. There did not appear to be a good plane between the nerve fascicles and the tumor. Careful dissection was performed to reveal a safe entry zone. This was incised and multiple pieces were sent for pathology. Frozen section measured 1.1 × 0.5 × 0.2 cm, and the permanent specimen measured 3.0 × 2.5 × 0.3 cm (in aggregate). Given multiple biopsy samples and conclusive histopathology, sampling bias was unlikely. Pathology revealed nerve and perineural soft tissue, with a dense infiltration of confluent plasma cells observed in the perineural tissue. No skeletal muscle or soft tissue invasion was reported in the pathology specimens. The frozen section was not consistent with a PNST but instead revealed plasma cell neoplasms with a high Ki-67 proliferation rate of 53.5%. Intraoperative histopathological analysis revealed nerve and perineural soft tissue that contained a dense infiltration of confluent plasma cells with abundant apoptotic debris. The surgical pathology team reported that these findings were consistent with a plasma cell neoplasm. Given the significantly infiltrative and hemorrhagic nature of the tumor, extensive encasement of the tibial nerve, and the frozen pathology, the surgical team decided to stop the resection at that point. The wound was then closed in meticulous fashion. The patient experienced no complications and tolerated the procedure well. The patient was transferred to the medical oncology service for postoperative management. Pathology and Molecular Diagnostic Testing Conventional karyotyping analysis postoperatively revealed no detectable clonal abnormalities of chromosome number or structure in 20 metaphase cells that were analyzed. Permanent pathology and molecular diagnostic testing revealed nerve and perineural soft tissue that contained a dense infiltration of confluent plasma cells with abundant apoptotic debris. Confirmatory flow cytometry revealed a large population of CD38-positive, CD45-dim, kappa light chain restricted cells that were CD138-positive, B2-microgloblin–positive, and CD56-dim/partial but CD19-negative. Postoperative Course The patient was transferred to the lymphoma/myeloma service after the attempted resection. Postoperative PET-CT imaging (Fig. 3A and B)revealed increased size and avidity of the ovoid popliteal fossa mass up to 15.0 × 4.8 × 3.9 cm. Scattered foci of gas, hemorrhage, and surrounding fat stranding were consistent with postprocedural changes. The patient received three courses of teclistamab. She received the second and third courses of teclistamab on postoperative days 16 and 19, respectively. Throughout her stay, the patient received 5 fractions of radiotherapy each with a dose of 400 cGy between postoperative days 14 and 19. No complications were reported after discharge from the hospital up to the latest follow-up at 60 days postsurgery. The patient has since received an additional course of teclistamab and intravenous immunoglobulin as an outpatient, which she is tolerating well. Postoperative PET scans. A: Increased size and avidity of ovoid popliteal fossa mass, measuring 15.0 × 4.8 × 3.9 cm (craniocaudal × anteroposterior × transverse dimensions). B:Additional views showing the extent the mass spread in the popliteal fossa. The arrows point to the mass. Informed Consent The necessary informed consent was obtained in this study. Discussion Observations In this work, we present a case of a tibial nerve sheath EMP in the setting of MM. Whereas primary EMPs arise in the absence of systemic disease, secondary EMPs form in the context of MM.11 This report illustrates a rare case of a secondary EMP invading the tibial nerve. Our case demonstrates that EMPs may be more common than reported in patients with MM. Although EMPs are more likely to arise in structures of the upper aerodigestive tract, they can form in any tissue in the body.11 This unique case emphasizes that secondary EMP should be kept on the differential for new peripheral nerve masses in the context of MM. Stuart and Smith reported a primary EMP in the superficial radial nerve that slowly enlarged over the course of 5 months.16 In that case, the patient had no systemic disease. The presentation was asymptomatic, without tenderness over the mass, sensory deficits, or neuropathic pain. An excisional biopsy and ultimately en bloc resection were performed under the assumption that the well-encapsulated, benign mass was a schwannoma. The definitive diagnosis of a solitary EMP was made following postoperative histopathological analysis. At the 4-year follow-up, the patient remained asymptomatic, had not developed any new masses, and had not developed MM. Our case differs in multiple ways. First, our patient was symptomatic and had a known history of aggressive MM. Our patient’s EMP was larger and faster growing. The tibial nerve carries both motor efferent and sensory afferent branches, so that masses affecting this nerve may cause greater morbidity. Diagnosing EMPs of peripheral nerves preoperatively might be challenging. Although MRI and PET imaging confirmed a well-vascularized tumor in our case, the rarity of EMPs conferred low suspicion on the care team’s differential diagnosis. Instead, the differential initially favored PNSTs such as schwannoma, neurofibroma, and MPNST. The lesion’s SUVmax of 11.7 and rapid growth raised suspicion for malignancy, and MPNST was included in the differential. However, multiple clinical factors made MPNST less likely: the patient had no history of neurofibromatosis type 1 or prior radiation therapy to the affected area, and the tumor was located in the tibial nerve, rather than more common MPNST sites such as the brachial or lumbosacral plexus or the sciatic nerve. Additionally, the lesion had relatively smooth margins, unlike the more irregular borders often seen in MPNSTs. Neurolymphomatosis and EMPs can both present with plasmacytic or plasmablastic morphology and may appear as extranodal masses, particularly in immunocompromised individuals.17,18 However, neurolymphomatosis typically manifests as multifocal or mononeuropathic dysfunction due to widespread neural infiltration, whereas EMP usually presents as a solitary, localized lesion.19 Differentiation can also be made based on systemic findings and molecular characteristics. EMP is distinguished by the absence of marrow or systemic involvement and typically lacks evidence of widespread disease.18,20,21 In contrast, lymphoplasmacytic lymphoma is characterized by the MYD88 L265P mutation, while plasmablastic lymphoma expresses plasma cell markers (CD38 and CD138), demonstrates a high Ki-67 proliferation index, and is frequently Epstein-Barr virus (EBV)-positive. EMP may share CD38 and CD138 expression but is typically EBV-negative.18,20,21 In our case, while neurolymphomatosis was considered in the differential, the lack of multifocal involvement and absence of diffuse nerve infiltration made this diagnosis less likely. Importantly, neurolymphomatosis is typically not treated with resection, but rather managed with systemic chemotherapy, often combined with localized radiotherapy, depending on the extent and distribution of disease. The lesion in our case demonstrated several features suggestive of a tumefactive process, including fusiform nerve enlargement, heterogeneous T2 signal, and marked contrast enhancement with central nonenhancement. While loss of the normal fascicular pattern—a hallmark of tumefactive hematological nerve lesions, as described by Murthy et al.—was not observed on our MRI, intraoperative findings revealed an indistinct fascicular architecture and lack of a clear dissection plane, suggesting extensive intraneural involvement.22 Murthy et al. describe a phasic mechanism of tumor spread in neurolymphomatosis and related hematological malignancies, where tumor cells infiltrate the nerve, extrude at weak points (typically branch junctions), and expand circumferentially within the subparaneurial space. Although originally described in lymphoma, this model may help explain the mass-like behavior and imaging appearance of EMPs involving peripheral nerves, as seen in our case. Recognizing these imaging signatures is crucial, as doing so may help distinguish these lesions from benign PNSTs and guide timely biopsy. In our case, the lesion’s imaging characteristics, rapid growth, and lack of a clear plane with the nerve influenced the decision to pursue an open surgical approach with intraoperative monitoring over image-guided biopsy, reflecting the importance of integrating tumefactive behavior into surgical planning. While an image-guided biopsy was considered to rule out malignancy, it was ultimately not pursued due to the risk of nerve damage. Preoperative MRI showed that the lesion was not clearly separable from adjacent neural structures, raising concern for inadvertent nerve injury during needle biopsy. Instead, an open approach was chosen to allow for intraoperative neuromonitoring and nerve stimulation, which would enable safe exposure and facilitate biopsy with minimal risk to nerve function. Although EMG was not performed in this case, it may have provided valuable information regarding the functional integrity of the tibial nerve and the extent and nature of nerve involvement. Incorporating electrophysiological studies into future cases may help guide diagnostic evaluation and surgical planning, especially when imaging findings are ambiguous. EMPs can be easily mistaken for other soft tissue masses, particularly when they arise in unusual locations such as peripheral nerves. In these cases, imaging and biopsy are critical for differentiating EMPs from more common entities like benign or malignant PNSTs. The standard of care varies significantly depending on the diagnosis: benign and malignant PNSTs are typically treated with excision, while MPNSTs may also benefit from radiotherapy and chemotherapy. For EMPs, complete resection is preferred when feasible. However, when resection poses high risk, such as in our case, where the lesion extensively encased the tibial nerve and lacked a clear surgical plane, a combination of limited surgical intervention and radiotherapy is often recommended. Radiation therapy alone may be used when surgery is not an option. Our case stands in contrast to previously reported examples, such as the superficial radial nerve EMP,11 which was successfully managed with complete resection and resulted in no recurrence or significant morbidity. As discussed above, radiation therapy with teclistamab was chosen to treat our tibial nerve EMP. On surgical exposure, the EMP in our patient was located in the popliteal fossa. Its extensive encasement of the tibial nerve and hemorrhagic nature ultimately dissuaded excision. Our team determined that the extent to which a subtotal resection could be achieved would be of marginal benefit in the context of such an aggressive disease. Importantly, if left untreated, solitary EMPs may progress to MM or systemic plasma cell neoplasms,23 underscoring the need for early recognition and appropriate, individualized management. The tumor’s type, location, size, and histopathological characteristics should all be carefully considered when selecting a treatment approach. To date, we only have 60 days of follow-up with the patient presented here, so we cannot discuss outcomes beyond that period. Although the postoperative course has been going as planned so far, we cannot provide radiological data to confirm regression of the tibial nerve tumor in response to therapy. Lessons This report highlights a rare case of an EMP invading the tibial nerve and underscores the importance of including EMPs in the differential diagnosis of PNSTs, particularly in patients with MM. Diagnosing peripheral nerve tumors preoperatively can be challenging, as imaging features often overlap between benign and malignant entities. However, findings such as rapid interval growth and high FDG uptake should raise suspicion for malignancy and prompt timely biopsy to guide appropriate management. In patients with a known history of malignancy, early tissue diagnosis is critical to avoid delays in treating potentially aggressive disease. The decision to obtain a biopsy, however, must be carefully balanced against the risk of iatrogenic nerve injury if imaging suggests involvement of neural structures. In such cases, an open surgical approach with intraoperative neuromonitoring may provide a safer and more informative alternative to image-guided biopsy. Ultimately, treatment decisions for peripheral nerve tumors should be individualized based on tumor location, size, growth characteristics, and histopathology. Acknowledgments Funding was received from the Department of Health and Human Services (HHS)/National Institutes of Health (NIH) (T32GM152349 to P.N.). Disclosures Dr. Fu reported personal fees from Stryker and Johnson & Johnson outside the submitted work. Author Contributions Conception and design: Fu, Nilchian. Acquisition of data: Fu, Nilchian, Reed, Kocharian. Analysis and interpretation of data: Nilchian, Reed, Kocharian. Drafting the article: Nilchian, Reed, Kocharian. Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Fu. Administrative/technical/material support: Nilchian. Clinical participation: Kocharian. Correspondence Kai-Ming Fu: NewYork-Presbyterian Hospital/Weill Cornell Medicine, New York, NY. kaf9045@med.cornell.edu. References